Why Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today?
4D Molecular Therapeutics FDMT shares are trading higher after the company released interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (wet AMD) patients. Data presented at the Angiogenesis, Exudation, and Degeneration 2024…
#amd #fdmt